Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADIL NASDAQ:ADTX NASDAQ:ADXN NASDAQ:AEON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.38+2.1%$0.38$0.22▼$1.30$8.30M14.09 million shs685,614 shsADTXAditxt$1.04+1.0%$1.20$0.81▼$9,800.00$2.21M1.51.56 million shs135,760 shsADXNAddex Therapeutics$8.03-0.8%$8.52$6.51▼$13.27$8.51M1.631,088 shs492 shsAEONAEON Biopharma$0.77+11.6%$0.77$0.38▼$115.57$8.70M0.711.63 million shs115,767 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+0.03%-5.68%-20.91%-46.06%-62.03%ADTXAditxt-0.96%0.00%-16.94%-40.80%-99.99%ADXNAddex Therapeutics-2.97%-0.37%-1.67%-3.26%+5.33%AEONAEON Biopharma-0.62%-11.54%-14.18%+29.21%-99.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals1.8781 of 5 stars3.52.00.00.01.90.00.6ADTXAditxt0.598 of 5 stars0.04.00.00.01.60.00.6ADXNAddex Therapeutics2.3777 of 5 stars3.53.00.00.00.00.80.6AEONAEON Biopharma2.9462 of 5 stars3.55.00.00.00.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.00Buy$8.002,004.71% UpsideADTXAditxt 0.00N/AN/AN/AADXNAddex Therapeutics 3.00Buy$30.00273.83% UpsideAEONAEON Biopharma 3.00Buy$360.0046,659.32% UpsideCurrent Analyst Ratings BreakdownLatest ADTX, ADIL, AEON, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ADILAdial PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.26 per shareN/AADTXAditxt$12.05K182.96N/AN/A$5.66 per share0.18ADXNAddex Therapeutics$460K18.49N/AN/A$10.37 per share0.77AEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.05N/AN/AN/AN/A-191.31%-153.59%N/AADTXAditxt-$34.45MN/A0.00∞N/A-206,431.38%-316.98%-80.88%N/AADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)AEONAEON Biopharma-$36.63M-$6.084.28N/AN/AN/AN/A-994.63%N/ALatest ADTX, ADIL, AEON, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ADTXAditxtN/A-$3.45N/A-$3.45N/AN/A8/13/2025Q2 2025ADILAdial Pharmaceuticals-$0.22-$0.18+$0.04-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AADTXAditxtN/AN/AN/AN/AN/AADXNAddex TherapeuticsN/AN/AN/AN/AN/AAEONAEON BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A5.025.02ADTXAditxtN/A0.020.08ADXNAddex TherapeuticsN/A3.023.02AEONAEON BiopharmaN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ADTXAditxt15.54%ADXNAddex Therapeutics16.14%AEONAEON Biopharma22.78%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%ADTXAditxt0.01%ADXNAddex Therapeutics15.00%AEONAEON Biopharma0.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2021.83 million20.90 millionNo DataADTXAditxt602.12 million2.12 millionNo DataADXNAddex Therapeutics301.06 million901,000Not OptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableADTX, ADIL, AEON, and ADXN HeadlinesRecent News About These CompaniesAeon Biopharma Advances Biosimilar DevelopmentAugust 13, 2025 | msn.comAEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comAEON Biopharma, Inc. (AEON) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comHexagon launches AEON, a humanoid built for industryJune 17, 2025 | prnewswire.comAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711May 23, 2025 | globenewswire.comJost Fischer Purchases 50,000 Shares of AEON Biopharma, Inc. (NASDAQ:AEON) StockMay 22, 2025 | insidertrades.comAEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual ConferenceMay 21, 2025 | nasdaq.comAEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025May 19, 2025 | globenewswire.comAEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comAEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing ComplianceApril 25, 2025 | globenewswire.comAEON Biopharma Announces Inducement Awards for New CEO Rob BancroftApril 23, 2025 | nasdaq.comAeon Biopharma appoints Rob Bancroft as CEOApril 21, 2025 | msn.comAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711April 21, 2025 | globenewswire.comAEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive OfficerApril 21, 2025 | globenewswire.comBotulinum Toxin Market Forecast 2025-2030: Competitive Positioning, Strategies and Market Share AnalysisApril 14, 2025 | uk.finance.yahoo.comMineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1April 1, 2025 | msn.comAEON Biopharma announces leadership change amid growth strategyMarch 29, 2025 | investing.comAeon Biopharma CEO to Step Down Next WeekMarch 28, 2025 | ocbj.comOAEON Biopharma Announces CEO TransitionMarch 27, 2025 | globenewswire.comAEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025March 26, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADTX, ADIL, AEON, and ADXN Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.38 +0.01 (+2.15%) Closing price 04:00 PM EasternExtended Trading$0.37 -0.01 (-1.87%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Aditxt NASDAQ:ADTX$1.04 +0.01 (+0.97%) Closing price 03:59 PM EasternExtended Trading$1.06 +0.02 (+2.40%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Addex Therapeutics NASDAQ:ADXN$8.02 -0.07 (-0.80%) Closing price 03:43 PM EasternExtended Trading$8.02 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.AEON Biopharma NASDAQ:AEON$0.77 +0.08 (+11.58%) Closing price 04:00 PM EasternExtended Trading$0.73 -0.04 (-5.05%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.